IRON Stock Forecast & Price Target

Disc Medicine is well-positioned for success due to its robust pipeline and upcoming FDA discussions, particularly for selcodebart as its 56% major anemia response rate is expected to generate substantial value. With its current Buy rating and $120 price target based on its 2035 discounted revenue estimate of $561M, as well as the probability of success for its various assets, Disc Medicine is primed for growth in the coming years. However, key risks to consider include regulatory approval, competition in the market, and potential additional funding needed for development and commercialization.

Disc Medicine is facing challenges due to their portfolio progression, resulting in a widened operating loss for the quarter. Despite a positive clinical readout expected for their EPP treatment, bitopertin, the FDA's CRL adds uncertainty to their regulatory approval process and may delay potential revenue streams. Additionally, while their pipeline includes promising treatments for various hematologic diseases, the company's high R&D expenses and decreased bitopertin costs are cause for concern for their financial stability in the long term.